Oncology Institute director awarded 29,116 RSUs

TZOUMAKAS KIMBERLY JO reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

TZOUMAKAS KIMBERLY JO reported acquisition or exercise transactions in this Form 4 filing.

Oncology Institute, Inc. director TZOUMAKAS KIMBERLY JO received a grant of 29,116 restricted stock units on July 27, 2026, each entitling her to one share of common stock upon settlement. These RSUs vest in full at the 2027 annual meeting of stockholders, bringing her direct holdings to 46,301 shares.

Insider Trade Summary

Grant/Award: 29,116 shares

Grant/Award 1 txn

Insider TZOUMAKAS KIMBERLY JO

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	29,116	$0.00	$0.00

Holdings After Transaction: Common Stock — 46,301 shares (Direct)

Footnotes (1)

1. F1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.

Key Figures

RSUs granted: 29,116 shares Grant price: $0.0000 per share Direct holdings after grant: 46,301 shares +1 more

4 metrics

RSUs granted 29,116 shares Grant of restricted stock units on 2026-07-27

Grant price $0.0000 per share Reported transaction price for RSU award

Direct holdings after grant 46,301 shares Common stock directly held following the RSU grant

Vesting year 2027 RSUs vest in full at the 2027 annual meeting of stockholders

Key Terms

restricted stock units (RSUs), vest in full, annual meeting of stockholders

3 terms

restricted stock units (RSUs) financial

"Represents grant of restricted stock units (RSUs), each of which entitle"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

vest in full financial

"The RSUs vest in full on the date of the Issuer's 2027"

annual meeting of stockholders regulatory

"on the date of the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TOI report for director TZOUMAKAS KIMBERLY JO?

Director TZOUMAKAS KIMBERLY JO received 29,116 restricted stock units of Oncology Institute, Inc. (TOI) on July 27, 2026. These RSUs convert into common stock on settlement and vest fully at the company’s 2027 annual meeting of stockholders.

How many shares does the TOI director hold after the latest Form 4 transaction?

Following the RSU grant, the director directly holds 46,301 shares of Oncology Institute common stock. This figure reflects the total direct ownership position reported after the July 27, 2026 restricted stock unit award.

When do the 29,116 RSUs granted by TOI to its director vest?

The 29,116 restricted stock units granted to the director vest in full on the date of Oncology Institute’s 2027 annual meeting of stockholders, conditioned on the director’s continued service with the company through that vesting date.

What does each RSU granted by Oncology Institute (TOI) to the director represent?

Each of the 29,116 restricted stock units entitles the reporting person to receive one share of Oncology Institute’s common stock upon settlement, according to the grant’s terms described in the insider transaction footnote.

Was the TOI director’s July 27, 2026 RSU grant a market purchase or a compensation award?

The transaction is coded as a grant or award acquisition, not a market purchase. The RSUs were awarded at a reported price of $0.0000 per share, reflecting a stock-based compensation grant rather than an open-market buy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/29/2026 - 06:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TZOUMAKAS KIMBERLY JO

(Last) (First) (Middle)

18000 STUDEBAKER ROAD,

SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		A(1)		29,116	A	$0.00	46,301	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.

	/s/ Mark Hueppelsheuser, Attorney-in-fact for Kimberly J. Tzoumakas	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)